期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 158, 期 4, 页码 519-522出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1365-2141.2012.09165.x
关键词
AML; elderly; chemotherapy; clinical trial
类别
资金
- Cancer Research UK
The AML16 trial evaluated the combination of the farnesyltransferase inhibitor, tipifarnib, and low dose cytarabine (LDAC) in older acute myeloid leukaemia (AML) patients in a Pick a Winner design. The aim was to double remission rates compared to LDAC, with initial evaluation after 100 patients. Failure to improve remission would result in discontinuation. A total of 65 patients, median age 74 years (range 6286), were randomized. After reviewing the first 45 patients, the Data Monitoring Committee concluded that the overall aspirations would not be met and recommended closure. The addition of tipifarnib had no effect on response, toxicity or survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据